Table 3.
Radiofrequency Ablation for Malignant Biliary Obstruction
| Study | n | Malignancy | Mean/median stent patency | Mean/median survival | Adverse events |
|---|---|---|---|---|---|
| Steel et al. (2011) [18] | 22 | (73% pancreatic, 27% CCA) | 114 (0–498) days | 90-day: 76.2% | 19% |
| Figueroa-Barojas et al. (2013) [19] | 20 | CCA 11 | N/A | N/A | 35% |
| Pancreatic Ca 7 | |||||
| IPMN 1 | |||||
| Gastric Ca 1 | |||||
| Dolak et al. (2014) [20] | 58 (84 sessions) | Majority Klatskin (77.6%) | 170 days | 10.6 mo | 14.3% (12/84 RFA sessions) |
| Sharaiha et al. (2014) [21] | 64 (RFA 26) | Pancreatic Ca 28 | N/A | 5.9 mo | 7.7% |
| CCA 36 | |||||
| Kallis et al. (2015) [22] | 23 | Pancreatic Ca | 472 days | 226 days | N/A |
| Liang et al. (2015) [23] | 76 (34 RFA) | All CCA | 9.5 (4.5–14) mo | N/A | 26.5% |
| Hu et al. (2016) [24] | 63 | Hilar CCA 19 | 150 days | 311 days | N/A |
| RFA 32 | Mid CBD 35 | 117 days | 172 days | ||
| Stenting 31 | Ampullary 9 | ||||
| Laquière et al. (2016) [25] | 12 | Bismuth I/II 7 | N/A | 12.3 mo (3–32) | 16.7% |
| III/IV 5 | |||||
| Wang et al. (2016) [26] | 12 (20 RFA sessions) | CCA 9 | 125 days | 232 days | Fever- 2 |
| Liver Ca 1 | PEP- 1 | ||||
| Gastric Ca 1 | |||||
| Choledochal cyst 1 | |||||
| Yang (2018) [28] | 65 | Extrahepatic CCA | 6.8 mo vs. 3.4 mo (p=0.02) | 13.2±0.6 vs. 8.3±0.5 (p<0.001) | 6.3% vs. 9.1% |
| RFA+ stent 32 | |||||
| Stent only 33 |
Ca, carcinoma; CBD, common bile duct; CCA, cholangiocarcinoma; IPMN, intraductal papillary mucinous neoplasm; N/A, not available; PEP, post endoscopic retrograde cholangiopancreatography pancreatitis; RFA, radiofrequency ablation.